SHANGHAI – Beigene Co. Ltd., of Beijing, is advancing its small-molecule Bruton’s tyrosine kinase (BTK) inhibitor candidate, BGB-3111, in a global phase III trial for patients with Waldenström’s macroglobulinemia (WM, or lymphoplasmacytic lymphoma), a type of non-Hodgkin lymphoma.